Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER Database
Authors:
- Ayrton BangoloAyrton Bangolo
- Behzad AmoozgarBABehzad Amoozgar
- Abhishek ThapaATAbhishek Thapa
- Wardah BajwaWardah Bajwa
- Vignesh K. NageshVNVignesh K. Nagesh
- Yaryna NyzhnykYNYaryna Nyzhnyk
- Rakshanda BanuRBRakshanda Banu
- Tirth BhavsarTBTirth Bhavsar
- Lili ZhangLZLili Zhang
- Olga VelichkoOVOlga Velichko
- Challa Mani Shankar ReddyCRChalla Mani Shankar Reddy
- Edwina EssumanEEEdwina Essuman
Open Access
- 31 October 2024
- journal article
- research article
- Published by MDPI AG in Medical Sciences
- Vol. 12 (4) , 60
Abstract
Background: Chronic Myelomonocytic Leukemia (CMML) is a rare and aggressive form of leukemia with characteristics of both myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDSs). This study aims to explore the clinical features, survival outcomes, and prognostic factors in CMML patients over the past 20 years using a large sample. Methods: The study data from 4124 patients diagnosed with CMML between 2000 and 2017 were sourced from the SEER database. Demographic and clinical characteristics, along with overall and cancer-specific mortality, were examined. Factors with a p-value < 0.01 in univariate Cox regression were included in the multivariate Cox model to identify independent prognostic factors, with hazard ratios (HRs) greater than one indicating adverse outcomes. Results: The majority of the cohort were male (61.57%), and most diagnoses occurred between ages 60–79 (55.16%), with a small percentage under 40 (1.41%). Non-Hispanic whites represented the largest racial group (79.03%). Multivariate analysis showed higher mortality in males, those aged 80+, residents in metropolitan areas with populations between 250,000 and 1 million, single or widowed individuals, and those who underwent chemotherapy. Conversely, lower mortality was associated with an annual income of $75,000+. Conclusions: CMML remains a rare and highly aggressive hematologic disorder. This U.S.-based retrospective cohort study identified male gender, advanced age, single or widowed status, and chemotherapy as independent poor prognostic factors. While it is expected that older patients and those requiring chemotherapy would have a poorer prognosis, the higher mortality risk in single or widowed patients, as well as males, warrants further investigation. The early involvement of family and community support may help reduce mortality in these groups, suggesting a need for larger prospective studies to explore these associations further.Keywords
This publication has 37 references indexed in Scilit:
- Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and managementAmerican Journal of Hematology, 2024
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 2024
- DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk diseaseAmerican Journal of Hematology, 2019
- Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registriesCancer Epidemiology, 2019
- Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance statusCancer Medicine, 2018
- Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 2018
- The effect of marital status by age on patients with colorectal cancer over the past decades: a SEER-based analysisInternational Journal of Colorectal Disease, 2018
- Therapy related‐chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMMLAmerican Journal of Hematology, 2017
- The effect of marital status on breast cancer-related outcomes in women under 65: A SEER database analysisThe Breast, 2017
- Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemiaAmerican Journal of Hematology, 2014